Last reviewed · How we verify

Uritos® — Competitive Intelligence Brief

Uritos® (Uritos®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Uricosuric agent / URAT1 inhibitor. Area: Rheumatology / Metabolic Disorders.

phase 3 Uricosuric agent / URAT1 inhibitor URAT1 (urate transporter 1) Rheumatology / Metabolic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

Uritos® (Uritos®) — R-Pharm. Uritos is a uricosuric agent that increases urinary excretion of uric acid by inhibiting renal urate reabsorption.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Uritos® TARGET Uritos® R-Pharm phase 3 Uricosuric agent / URAT1 inhibitor URAT1 (urate transporter 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Uricosuric agent / URAT1 inhibitor class)

  1. R-Pharm · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Uritos® — Competitive Intelligence Brief. https://druglandscape.com/ci/uritos. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: